The role of reactive-center loop mobility in the serpin inhibitory mechanism

Advances in Experimental Medicine and Biology

Volumn 425, Issue , 1997, Pages 99-108

  Lawrence, Daniel A ^a  

^a HOLLAND LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; OVALBUMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITOR; SUICIDE SUBSTRATE;

AMINO TERMINAL SEQUENCE; ARTICLE; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITOR COMPLEX; ENZYME INHIBITOR INTERACTION; ENZYME MECHANISM; FLUORESCENCE ANALYSIS; PRIORITY JOURNAL; PROTEINASE INHIBITION; SEQUENCE ANALYSIS; X RAY CRYSTALLOGRAPHY;

EID: 0031437136     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5391-5_10     Document Type: Article

References (30)

1. Huber R, Carrell RW (1989): Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochem 28:8951-8966.
2. Doolittle RF (1983): Angiotensinogen is related to the antitrypsin-antithrombin-ovalbumin family. Science 222:417-419.
3. Hunt LT, Dayhoff MO (1980): A surprising new protein superfamily containing ovalbumin, antithrombin III, and alphal-proteinase inhibitor. Biochem Biophys Res Commun 95:864-871.
4. Sasaki T ( 1991 ): Patchwork-structure serpins from silkworm (Bombyx mori) larval hemolymph. Eur J Biochem 202:255-261.
5. Komiyama T, Ray CA, Pickup DJ, Howard AD, Thornberry NA, Peterson EP, Salvesen G (1994): Inhibition of interleukin-1β converting enzyme by the cowpox virus serpin CrmA. An example of cross-class inhibition. J Biol Chem 269:19331-19337.
6. Loebermann H, Tokuoka R, Deisenhofer J, Huber R (1984): Human α1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol 177:531-557.
7. Carrell RW, Boswell DR (1986): Serpins: the superfamily of plasma serine proteinase inhibitors. In: Proteinase Inhibitors, AJ Barrett, G Salvesen, eds. Elsevier Science Publishers (Biomedical Division), Amsterdam, pp. 403-420.
8. Sprang SR (1992): The latent tendencies of PAI-1. Trends Biochem Sci 17:49-50.
9. Carrell RW, Owen MC (1985): Plakalbumin, alpha-1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis. Nature 317:730-732.
10. Gettins P, Harten B (1988): Properties of thrombin- and elastase-modified human antithrombin III. Biochem 27:3634-3639.
11. Bruch M, Weiss V, Engel J (1988): Plasma serine proteinase inhibitors (serpins) exhibit major conformational changes and a large increase in conformational stability upon cleavage at their reactive sites. J Biol Chem 263:16626-16630.
12. Lawrence DA, Olson ST, Palaniappan S, Ginsburg D (1994): Serpin reactive-center loop mobility is required for inhibitor function but not for enzyme recognition. J Biol Chem 269:27657-27662.
13. Schreuder HA, de Boer B, Dijkema R, Mulders J, Theunissen HJM, Grootenhuis PDJ, Hol WGJ (1994): The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nature Structural Biology 1:48-54.
14. Carrell RW, Stein PE, Fermi G, Wardell MR (1994): Biological implications of a 3 Å structure of dimeric antithrombin. Structure 2:257-270.
15. Stein PE, Leslie AGW, Finch JT, Turnell WG, McLaughlin PJ, Carrell RW (1990): Crystal structure of ovalbumin as a model for the reactive centre of serpins. Nature 347:99-102.
16. Wei A, Rubin H, Cooperman BS, Christianson DW (1994): Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop. Nature Structural Biology 1:251-258.
17. 14 region of the putative reactive bond loop of the inhibitor. J Biol Chem 267:1976-1982.
18. Björk I, Nordling K, Larsson I, Olson ST (1992): Kinetic characterization of the substrate reaction between a complex of antithrombin with a synthetic reactive-bond loop tetradecapeptide and four target proteinases of the inhibitor. J Biol Chem 267:19047-19050.
19. 1-antitrypsin by a peptide sequentially similar to β-strand s4A. Eur J Biochem 194:51-56.
20. Carrell RW, Evans DL, Stein PE (1991): Mobile reactive centre of serpins and the control of thrombosis. Nature 353:576-578.
21. Kvassman J, Lawrence D, Shore J (1995): The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into β-sheet A. J Biol Chem 270: 27942-27947.
22. Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ (1992): Structural basis of latency in plasminogen activator inhibitor-1. Nature 355:270-273.
23. Lawrence DA, Olson ST, Palaniappan S, Ginsburg D (1994): Engineering plasminogen activator inhibitor-1 (PAI-1) mutants with increased functional stability. Biochem 33:3643-3648.
24. Hekman CM, Loskutoff DJ (1985): Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 260:11581-11587.
25. Lomas DA, Elliot PR, Chang W-SW, Wardell MR, Carrell RW (1995): Preparation and characterization of latent α1-antitrypsin. J Biol Chem 270:5282-5288.
26. Lawrence DA, Strandberg L, Ericson J, Ny T (1990): Structure-function studies of the SERPIN plasminogen activator inhibitor type 1: analysis of chimeric strained loop mutants. J Biol Chem 265:20293-20301.
27. Carrell RW, Evans DLI (1992): Serpins: mobile conformations in a family of proteinase inhibitors. Curr Opin Struct Biol 2:438-446.
28. Shore JD, Day DE, Francis-Chmura AM, Verhamme I, Kvassman J, Lawrence DA, Ginsburg D (1994): A fluorescent probe study of plasminogen activator inhibitor-1: Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J Biol Chem 270:5395-5398.
29. Lawrence DA, Ginsburg D, Day DE, Berkenpas MB, Verhamme IM, Kvassman J-O, Shore JD (1995): Serpin-Protease Complexes are Trapped as Stable Acyl-Enzyme Intermediates. J Biol Chem 270:25309-25312.
30. Fa M, Karolin J, Aleshkov S, Strandberg L, Johansson LB-Å, Ny T (1995): Time-Resolved Polarized Fluorescence Spectroscapy Studies of Plasminogen Activator Inhibitor Type 1: Conformational Changes of the Reactive Center upon Interations with Target proteases.Vitronectin and Heparin. Biochem 34:13833-13840.